Thomas J. Herzog , MD

Bachelor's Degree: Miami University Cincinnati, OH, 1982 (Zoology)

Medical Degree: University of Cincinnati Cincinnati, OH, 1986 (Obstetrics and Gynecology Gynecologic Oncology)

Residency: Good Samaritan Hospital Cincinnati, OH, 1990 (Obstetrics and Gynecology)

Fellowship: Washington University School of Medicine St. Louis, MO, 1993 (Gynecologic Oncology)

American Board of Obstetrics and Gynecology (Gynecologic Oncology) (Certification Date: 04-09-1997 ) - (Recertification Date: to 12-31-2024 )

American Board of Obstetrics and Gynecology (Certification Date: 11-17-1995 ) - (Recertification Date: to 12-31-2024 )

Gynecologic Oncology

Obstetrics and Gynecology

Oncology

Adenomyosis

Adnexal Disease

Adnexal Tumors

Cervical Cancer

Dysgerminoma

Embryonal Carcinoma

Embryonal Tumors

Endometrial Cancer

Endometrial Stromal Sarcoma

Endometriosis

Fallopian Tube Cancer

Fibroids

Germ Cell and Embryona Cancers

Germ Cell Tumor

Gestational Trophoblastic Neoplasia

Human Papilloma Virus (HPV)

Krukenberg Tumor

Other Complicated Gynecologic Cancers

Ovarian Cancer

Ovarian Cyst

Pelvic Cancers

Pelvic Masses

Placenta Accreta

Precancer in the Vagina

Precancer in the Vulva

Precancers in the Cervix

Uterine Fibroids (Uterine leiomyoma)

Uterine Hemorrhage

Uterine Polyps (Endometrial Polyps)

Uterine Sarcoma

Vaginal Cancer

Vulvar Cancer

Gynecologic Oncology

Obstetrics and Gynecology

Investigators:Herzog, Thomas 02-01-2022 -02-01-2025 Alkermes Ph 3, Multicenter, Open-Label, Randomized Study of Nemvaleukin Alfa in Comb w/Pembrolizumab vs Investigator's Choice Chemo in Pts w/Platinum-Resistant Epithelial Ovarian, Fallopian or PPC (ARTISTRY-7) Role:PI 447383.15 Hold Level:Industry

Grant: #MK-2870-020/GOG-3101 Investigators:Herzog, Thomas 03-12-2025 -03-12-2028 Merck Sharp & Dohme LLC A Phase 3, Randomized, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan Maintenance Treatment With or Without Bevacizumab Versus Standard of Care After Seco Role:PI 393900.58 Hold Level:Industry

Grant: #GOG-3107 (PRO1184-002/GCT1184-02) Investigators:Herzog, Thomas 04-30-2025 -04-30-2028 Genmab US, Inc A Phase 3 Randomized, Open-label Study of Rinatabart Sesutecan (Rina-S) versus Treatment of Investigator's Choice in Patients with Platinum Resistant Ovarian Cancer Role:PI 134285.56 Hold Level:Industry

Peer Reviewed Publications

Herzog T.J.;Monk B.J.;Rose P.G.;Braly P.;Hines J.F.;Bell M.C.;Wenham R.M.;Secord A.A.;Roman L.D.;Einstein M.H.;Drake R.D.;Childs B.H. (01-01-2014. ) A phase II trial of oxaliplatin, docetaxel, and bevacizumab as first-line therapy of advanced cancer.Gynecologic Oncology, , 132 (3 ) ,517-525 More Information

Wright J.;Ananth C.;Tsui J.;Glied S.;Burke W.;Lu Y.;Neugut A.;Herzog T.;Hershman D. (01-01-2014. ) Comparative effectiveness of upfront treatment strategies in elderly women with ovarian cancer.Cancer, , 120 (8 ) ,1246-1254 More Information

Du Bois A.;Floquet A.;Kim J.W.;Rau J.;Del Campo J.M.;Friedlander M.;Pignata S.;Fujiwara K.;Vergote I.;Colombo N.;Mirza M.R.;Monk B.J.;Kimmig R.;Ray-Coquard I.;Zang R.;Diaz-Padilla I.;Baumann K.H.;Mouret-Reynier M.A.;Kim J.H.;Kurzeder C.;Lesoin A.;Vasey P.;Marth C.;Canzler U.;Scambia G.;Shimada M.;Calvert P.;Pujade-Lauraine E.;Kim B.G.;Herzog T.J.;Mitrica I.;Schade-Brittinger C.;Wang Q.;Crescenzo R.;Harter P. (10-20-2014. ) Incorporation of pazopanib in maintenance therapy of ovarian cancer.Journal of Clinical Oncology, , 32 (30 ) ,3374-3381 More Information

Burke W.M.;Orr J.;Leitao M.;Salom E.;Gehrig P.;Olawaiye A.B.;Brewer M.;Boruta D.;Villella J.;Herzog T.;Shahin F.A. (01-01-2014. ) Corrigendum to "Endometrial cancer: A review and current management strategies: Part I" [Gynecol Onc.Gynecologic Oncology, , 135 (3 ) ,625 More Information

Floquet A.;Vergote I.;Colombo N.;Fiane B.;Monk B.J.;Reinthaller A.;Calvert P.;Herzog T.J.;Meier W.;Kim J.W.;Campo J.M.D.;Friedlander M.;Pisano C.;Isonishin S.;Crescenzo R.J.;Barrett C.;Wang K.;Mitrica I.;Bois A.D. (01-01-2015. ) Progression-free survival by local investigator versus independent central review: Comparative analy.Gynecologic Oncology, , 136 (1 ) ,37-42 More Information

Berek J.S.;Edwards R.P.;Parker L.P.;Demars L.R.;Herzog T.J.;Lentz S.S.;Morris R.T.;Akerley W.L.;Holloway R.W.;Method M.W.;Plaxe S.C.;Walker J.L.;Friccius-Quecke H.;Krasner C.N. (01-01-2014. ) Catumaxomab for the treatment of malignant ascites in patients with chemotherapy-refractory ovarian .International Journal of Gynecological Cancer, , 24 (9 ) ,1583-1589 More Information

Herzog T.;Coleman R.;Monk B.;Armstrong D.;Alvarez R. (05-01-2015. ) In assessing surrogate clinical trial end points: Drug safety is a requisite.Journal of Clinical Oncology, , 33 (13 ) ,1511-1512 More Information

Jackson A.;Eisenhauer E.;Herzog T. (01-01-2015. ) Emerging therapies: Angiogenesis inhibitors for ovarian cancer.Expert Opinion on Emerging Drugs, , 20 (2 ) ,331-346 More Information

Previs R.;Leath C.;Coleman R.;Herzog T.;Krivak T.;Brower S.;Tian C.;Secord A. (01-01-2015. ) Evaluation of in vitro chemoresponse profiles in women with Type i and Type II epithelial ovarian ca.Gynecologic Oncology, , 138 (2 ) ,267-271 More Information

Academic - University of Cincinnati Cancer Institute
3255 Eden Avenue, Suite 250B
Cincinnati  Ohio, 45019
Phone: 513-558-2177
Fax: 513-558-2666
thomas.herzog@uc.edu